Abstract
Molecular imaging with positron emission tomography is a powerful tool in bladder cancer management. In this review, we aim to address the current place of the PET imaging in bladder cancer care and offer perspectives on potential future radiopharmaceutical and technological advancements. A special focus is given to the following: the role of [(18)F] 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in the clinical management of bladder cancer patients, especially for staging and follow-up; treatment guided by [(18)F]FDG PET/CT; the role of [(18)F]FDG PET/MRI, the other PET radiopharmaceuticals beyond [(18)F]FDG, such as [(68)Ga]- or [(18)F]-labeled fibroblast activation protein inhibitor; and the application of artificial intelligence.